Lantheus Medcl Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LANTHEUS MEDCL
LANTHEUS MEDCL has five approved drugs.
There are eleven US patents protecting LANTHEUS MEDCL drugs.
There are eighty-one patent family members on LANTHEUS MEDCL drugs in seventeen countries and seven supplementary protection certificates in five countries.
Summary for Lantheus Medcl
| International Patents: | 81 |
| US Patents: | 11 |
| Tradenames: | 6 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Lantheus Medcl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lantheus Medcl | XENON XE 133 | xenon xe-133 | INJECTABLE;INJECTION | 017283-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Lantheus Medcl | DEFINITY RT | perflutren | INJECTABLE;INTRAVENOUS | 021064-002 | Nov 17, 2020 | RX | Yes | Yes | 11,266,750 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-001 | Dec 22, 2008 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | RX | Yes | Yes | 11,529,431 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | RX | Yes | Yes | 12,161,730 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Lantheus Medcl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | 6,033,645 | ⤷ Start Trial |
| Lantheus Medcl | DEFINITY | perflutren | INJECTABLE;INTRAVENOUS | 021064-001 | Jul 31, 2001 | 5,585,112 | ⤷ Start Trial |
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-001 | Dec 22, 2008 | 8,394,356 | ⤷ Start Trial |
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-002 | Dec 22, 2008 | 6,676,929 | ⤷ Start Trial |
| Lantheus Medcl | ABLAVAR | gadofosveset trisodium | SOLUTION;INTRAVENOUS | 021711-002 | Dec 22, 2008 | 7,229,606 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Lantheus Medcl Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 318965 | ⤷ Start Trial |
| Taiwan | I821755 | ⤷ Start Trial |
| Taiwan | I853789 | ⤷ Start Trial |
| China | 115531560 | ⤷ Start Trial |
| Australia | 2022201065 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lantheus Medcl Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0712293 | C300267 | Netherlands | ⤷ Start Trial | PRODUCT NAME: PERFLUTREN BEVATTENDE LIPIDE-MICROBOLLEN; REGISTRATION NO/DATE: EU/1/06/361/001 20060920 |
| 0712293 | 0790017-8 | Sweden | ⤷ Start Trial | PRODUCT NAME: LIPIDMIKROSFAERER INNEHALLANDE PERFLUTREN; REG. NO/DATE: EU/1/06/361/001 20060920 |
| 0806968 | SPC/GB07/011 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 |
| 0806968 | PA2007003 | Lithuania | ⤷ Start Trial | PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REG NO/DATE: EU/1/05/313/001-009 20051005 |
| 0806968 | 07C0028 | France | ⤷ Start Trial | PRODUCT NAME: GADOFOSVESET TRISODIQUE; REGISTRATION NO/DATE: EU/1/05/313/001-009 20051003 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
